A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
QLC1101 is a selective reversible inhibitor of KRAS G12D, with the dosage form of capsules and administration route of oral administration. In the first-in-humans (FIH) study, the sponsor will explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of QLC1101 in subjects with advanced solid tumors harboring a KRAS G12D mutation. The FIH study includes dose escalation, PK expansion, and efficacy expansion.